RxDoctor Payments Data

Brandt Sanders

Gerontology · Lafayette, LANPI 1770049231

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations.

$2,756in general payments, 2019–2025

Across 120 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$619
  • Kestra Medical Technology Services, Inc.$512
  • Abiomed$463
  • Amgen$271
  • Abbott$188
  • Pfizer$141
  • plus $562 from 11 others

What the payments were for

  • Food & beverage$2,756100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,756 in reported general payments places this provider in the 80th percentile of 64 gerontology providers in Louisiana.

See all gerontology providers in Louisiana

Medicare billing

Part B allowed, 2024
$28,466
Medicare patients
323
Services billed
378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan39$33,851
EliquisApixaban20$16,132
XareltoRivaroxaban14$10,067
Nifedipine ErNifedipine108$1,518
Metoprolol Succinate118$1,497
Nebivolol Hcl20$1,096
Midodrine Hcl22$843
Ranolazine ErRanolazine19$837
Carvedilol133$786
Valsartan36$663
Isosorbide Mononitrate ErIsosorbide Mononitrate69$651
Furosemide248$628
Torsemide43$541
Amlodipine Besylate138$428
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$48$33,85139 claims
PfizerEliquis$141$16,13220 claims
Johnson & JohnsonXarelto$102$10,06714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 gerontology providers in Louisiana.

Other gerontology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →